Question 1

What is TH103?

Accepted Answer

TH103 is a Other.

Question 2

How often does TH103 appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was TH103 first tracked by Ergen?

Accepted Answer

First tracked on Jun 12, 2026.

Question 4

When was TH103 last mentioned in news?

Accepted Answer

Last active on Jun 12, 2026.

Question 5

What is TH103's current news sentiment?

Accepted Answer

Aggregate sentiment score: 20 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is TH103 in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving TH103?

Accepted Answer

Kalaris Therapeutics Presents TH103 Data (Jun 12, 2026, 6 articles).

Question 8

How did the "Kalaris Therapeutics Presents TH103 Data" event impact TH103?

Accepted Answer

TH103 is the lead asset of AirNexis Therapeutics, and the presentation of its Phase 1a clinical data is a significant step in its development as a treatment for retinal diseases.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.